Overall, our study provides a pre-clinical rationale for further studies aimed at evaluating the use of 2-N-6-BP and 2,6-DTP for the treatment of BRCA2-proficient castration-resistant prostate cancers and suggests that 6-TG and the PARP inhibitor olaparib may have similar therapeutic potential in the treatment of BRCA2-deficient advanced prostate cancers. Here, BRCA2 is linked to prostate carcinoma.